Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 2: From the National Multiple Sclerosis Society Case Conference Proceedings

Neurol Neuroimmunol Neuroinflamm. 2020 Dec 15;8(1):e930. doi: 10.1212/NXI.0000000000000930. Print 2021 Jan.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alemtuzumab / therapeutic use*
  • Etanercept / therapeutic use
  • Female
  • Humans
  • Immunologic Factors / therapeutic use*
  • Immunosuppressive Agents / therapeutic use
  • Leukoencephalopathy, Progressive Multifocal / chemically induced*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Natalizumab / adverse effects*
  • Plasma Exchange
  • Rituximab / therapeutic use*

Substances

  • Immunologic Factors
  • Immunosuppressive Agents
  • Natalizumab
  • Alemtuzumab
  • Rituximab
  • Etanercept